https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-27 / J. Neurooncol. 2007 Jan;81(2):139-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-27 / J. Neurooncol. 2007 Jan;81(2):139-482006-09-27 00:00:002019-02-15 08:59:54Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-18 / Int. J. Radiat. Oncol. Biol. Phys. 2006 Nov;66(4):1159-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-18 / Int. J. Radiat. Oncol. Biol. Phys. 2006 Nov;66(4):1159-672006-09-18 00:00:002019-02-15 08:35:26Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer > or =FIGO IIB „bulky“
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-15 / Cancer 2006 Sep;107(6):1373-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-15 / Cancer 2006 Sep;107(6):1373-822006-09-15 00:00:002006-09-15 00:00:00Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-14 / N. Engl. J. Med. 2006 Sep;355(11):1179-812006-09-14 00:00:002019-02-15 09:19:46Patient-specific dendritic-cell vaccines for metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-05 / J. Clin. Endocrinol. Metab. 2006 Nov;91(11):4571-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-05 / J. Clin. Endocrinol. Metab. 2006 Nov;91(11):4571-72006-09-05 00:00:002019-02-15 08:53:27Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Endocr. Relat. Cancer 2006 Sep;13(3):779-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Endocr. Relat. Cancer 2006 Sep;13(3):779-952006-09-01 00:00:002019-02-15 08:53:27Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Ai Zheng 2006 Sep;25(9):1082-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Ai Zheng 2006 Sep;25(9):1082-62006-09-01 00:00:002019-02-15 09:23:47[Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-82006-09-01 00:00:002019-02-15 09:24:14Basic overview of current immunotherapy approaches in urologic malignancy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-412006-09-01 00:00:002019-02-15 09:24:13Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-57
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / J. Immunother. 2006 Sep-Oct;29(5):545-572006-09-01 00:00:002019-02-15 09:19:45Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
